[go: up one dir, main page]

PE20120182A1 - Extruidos con sustancias activas con forma de agujas - Google Patents

Extruidos con sustancias activas con forma de agujas

Info

Publication number
PE20120182A1
PE20120182A1 PE2011001057A PE2011001057A PE20120182A1 PE 20120182 A1 PE20120182 A1 PE 20120182A1 PE 2011001057 A PE2011001057 A PE 2011001057A PE 2011001057 A PE2011001057 A PE 2011001057A PE 20120182 A1 PE20120182 A1 PE 20120182A1
Authority
PE
Peru
Prior art keywords
extruded
shape
glycerol
needles
active substances
Prior art date
Application number
PE2011001057A
Other languages
English (en)
Inventor
Venkata-Rangarao Kanikanti
Hans-Juergen Hamann
Peter Kleinebudde
Rieke-Christina Witzleb
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41785839&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120182(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of PE20120182A1 publication Critical patent/PE20120182A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN EXTRUDIDO QUE CONTIENE: A) UNA SUSTANCIA FARMACEUTICA ACTIVA EN FORMA DE AGUJAS CUYA RELACION ENTRE EL TAMANO DE PARTICULA Y EL DIAMETRO DE LA CADENA ES DE 1:15 A 1:25, EN DONDE EL DIAMETRO DE LA CADENA ES DE 0.5mm O MENOR; B) UNA BASE LIPIDICA COMO COADYUVANTE TALES COMO TRIMIRISTATO DE GLICEROL, TRIPALMITATO DE GLICEROL O TRIESTEARATO DE GLICEROL; Y C) UN AGENTE ANTIESTATICO TAL COMO POLIETILENGLICOL. LA EXTRUSION SE REALIZO POR DEBAJO DEL LIMITE INFERIOR DEL INTERVALO DE FUSION DE LA BASE CONTENIDA EN EL MISMO. DICHO EXTRUDIDO ENMASCARA EL SABOR DE CIERTAS SUSTANCIAS FARMACEUTICAS
PE2011001057A 2008-12-05 2009-11-24 Extruidos con sustancias activas con forma de agujas PE20120182A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102008060472 2008-12-05

Publications (1)

Publication Number Publication Date
PE20120182A1 true PE20120182A1 (es) 2012-02-24

Family

ID=41785839

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001057A PE20120182A1 (es) 2008-12-05 2009-11-24 Extruidos con sustancias activas con forma de agujas

Country Status (27)

Country Link
US (1) US20120034273A1 (es)
EP (1) EP2373287B1 (es)
JP (2) JP5860284B2 (es)
KR (1) KR20110096145A (es)
CN (1) CN102238940B (es)
AR (1) AR075106A1 (es)
AU (1) AU2009321822B2 (es)
BR (1) BRPI0922302B8 (es)
CA (1) CA2745456A1 (es)
CL (1) CL2011001207A1 (es)
CO (1) CO6440550A2 (es)
CR (1) CR20110285A (es)
DO (1) DOP2011000160A (es)
EC (1) ECSP11011080A (es)
ES (1) ES2685472T3 (es)
IL (1) IL212846A0 (es)
MX (1) MX2011005572A (es)
NI (1) NI201100103A (es)
NZ (1) NZ593217A (es)
PE (1) PE20120182A1 (es)
RU (1) RU2549450C2 (es)
SV (1) SV2011003919A (es)
TW (1) TWI522114B (es)
UA (1) UA105648C2 (es)
UY (1) UY32287A (es)
WO (1) WO2010063387A1 (es)
ZA (1) ZA201104145B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU231017B1 (hu) * 2012-05-08 2019-11-28 LAVET Gyógyszeripari Kft. Praziquantel tartalmú ízfedett formulációk
BR112015023435B1 (pt) * 2013-03-15 2022-05-03 Douglas Robert Cleverly Formulação mastigável estável sob armazenagem e método de fabricação de uma formulação mastigável, palatável e estável sob armazenagem
IN2013MU03583A (es) * 2013-11-14 2015-07-31 Cipla Ltd
WO2019021191A1 (en) 2017-07-26 2019-01-31 Tgx Soft Chew, Llc STARCH-FREE MOUTH PRODUCT FOR VETERINARY APPLICATIONS
US20230372249A1 (en) 2020-09-04 2023-11-23 Elanco Us Inc. Palatable formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4402752B2 (ja) * 1997-05-19 2010-01-20 大日本住友製薬株式会社 免疫増強製剤
IT1298574B1 (it) * 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di microparticelle a base polimerica ottenute mediante estrusione e sferonizzazione
DE19916383A1 (de) * 1999-03-31 2000-10-05 Schering Ag Pharmazeutische Zusammensetzung mit einem Extrusionsstoff
RU2004106619A (ru) * 2001-08-06 2005-07-10 Эро-Селтик С.А. (Lu) Композиции опиоидного агониста, содержащие высвобождаемый и изолированный антагонист
WO2004002398A2 (en) * 2002-06-27 2004-01-08 Cilag Ag Spherical pellet containing a water-soluble active ingredient
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
US20050163842A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations
DE602004001969T2 (de) * 2004-02-20 2007-03-15 Mattern, Udo Orale pharmazeutische Zusammensetzung und Verfahren zu ihrer Herstellung
EP1690528A1 (de) * 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
JPWO2006090640A1 (ja) * 2005-02-23 2008-07-24 太陽化学株式会社 アミノ酸含有錠剤組成物および錠剤の製造方法
DE102005062270A1 (de) * 2005-12-24 2007-06-28 Bayer Technology Services Gmbh Geschmacksmaskierung von Pulvern
CA2665726C (en) * 2006-10-11 2016-04-19 Alpharma, Inc. Pharmaceutical compositions
DE102007026550A1 (de) * 2007-06-08 2008-12-11 Bayer Healthcare Ag Extrudate mit verbesserter Geschmacksmaskierung
CN101590020B (zh) * 2008-05-30 2012-02-08 上海新菲尔生物制药工程技术有限公司 一种对氨基水杨酸钠结肠定位给药系统

Also Published As

Publication number Publication date
EP2373287B1 (de) 2018-05-30
NZ593217A (en) 2013-05-31
BRPI0922302B1 (pt) 2020-09-15
ECSP11011080A (es) 2011-06-30
JP5860284B2 (ja) 2016-02-16
RU2549450C2 (ru) 2015-04-27
AR075106A1 (es) 2011-03-09
CA2745456A1 (en) 2010-06-10
EP2373287A1 (de) 2011-10-12
DOP2011000160A (es) 2011-06-30
WO2010063387A1 (de) 2010-06-10
MX2011005572A (es) 2011-06-16
JP2012510956A (ja) 2012-05-17
SV2011003919A (es) 2011-08-28
HK1163547A1 (en) 2012-09-14
UY32287A (es) 2010-06-30
CO6440550A2 (es) 2012-05-15
JP2015134812A (ja) 2015-07-27
IL212846A0 (en) 2011-07-31
BRPI0922302A2 (pt) 2016-01-05
RU2011127248A (ru) 2013-01-10
BRPI0922302B8 (pt) 2021-05-25
CN102238940A (zh) 2011-11-09
CR20110285A (es) 2011-09-27
CN102238940B (zh) 2014-07-30
CL2011001207A1 (es) 2011-10-28
KR20110096145A (ko) 2011-08-29
UA105648C2 (uk) 2014-06-10
TW201031422A (en) 2010-09-01
AU2009321822A1 (en) 2011-06-30
ZA201104145B (en) 2012-09-26
NI201100103A (es) 2012-04-16
US20120034273A1 (en) 2012-02-09
AU2009321822B2 (en) 2015-04-16
ES2685472T3 (es) 2018-10-09
TWI522114B (zh) 2016-02-21

Similar Documents

Publication Publication Date Title
PE20120182A1 (es) Extruidos con sustancias activas con forma de agujas
DOP2015000006A (es) Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles
MX388358B (es) Portador de sustancia fisiologicamente activa.
MX2017004256A (es) Metodo para desinfectar semillas comestibles, particularmente semillas productoras de mucilago.
MX2015013831A (es) Particulas abrasivas con formas particulares y metodos para elaborar las particulas.
DOP2016000132A (es) Sistema de administración farmacologico
CR20110448A (es) Composición sólida farmacéutica que contiene amlodipina y losartan con estabilidad mejorada
PE20140255A1 (es) Tableta dispersable en forma oral
CO6260054A2 (es) Extruidos con enmascaramiento del sabor mejorado
AR102198A1 (es) Proceso para reducir partículas subvisibles en una formulación farmacéutica
CR20150402A (es) Formulaciones farmacéuticas resistentes a la manipulación indebida
PE20181095A1 (es) Envase blister
DOP2012000217A (es) Pastillas de gelatina blanda con nicotina
PE20110943A1 (es) Formulacion oral solida de alisquireno
CR20150297A (es) Producto de comicronización que comprende acetato de ulipristal
CL2012000737A1 (es) Composición para entregar un agente activo que comprende una matriz de carbohidrato, un agente activo volátil atrapado adentro de la matriz de carbohidrato y un agente de expulsión atrapado dentro de la matriz de carbohidrato; sustrato seco para entregar un agente activo que comprende un sustrato y dicha composición de entrega.
CL2011000532A1 (es) Proceso para la obtencion de un film que comprende la incorporación de agentes antimicrobianos de origen natural en una estructura polimerica a través de un doble proceso de extrusión al material polimérico.
CO6460711A2 (es) Composición y método de entrega
CL2016001130A1 (es) Composiciones sólidas de triglicéridos y usos de estas
UY29441A1 (es) Oblea que contiene hormonas esteroides
PE20110925A1 (es) Formulacion galenica que comprende alisquireno y proceso para su preparacion mediante granulacion de extrusion fundida
CO7170181A2 (es) Nueva composición de alfentanilo para el tratamiento del dolor agudo
CL2012003209A1 (es) Metodo de sintesis de nanoparticulas de acido poli (lactico-glicolico) (plga) con pentoxifilina; composicion farmaceutica que comprende nanoparticulas de plga con pentoxifilina; y uso de las nanoparticulas de plga cargada con pentoxifilina en el tratamiento del alivio y prevencion del dolor cronico.
PE20121537A1 (es) Combinacion de teobromina con un descongestivo
ES2652253T3 (es) Preparación de vitamina

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed